May 31st 2023
Natalie S. Callander, MD, discusses several ongoing and planned clinical trials evaluating the use of novel therapeutic regimens in multiple myeloma.
April 6th 2023
Natalie S. Callander, MD, discusses the significance of the phase 3 ATLAS, phase 2 FORTE, and phase 2 MASTER trials in patients with multiple myeloma.
March 23rd 2023
Natalie S. Callander, MD, discusses the potential benefits of referring patients with multiple myeloma to CAR T-cell therapy earlier in their disease course.
April 2nd 2021
Jason Porter, MD, Subramanian Janakiraman, MD, Natalie S. Calendar, MD, Parameswaran Hari, MD, MRCP, and Kevin Kalinsky, MD, MS, discuss the importance of the Institutional Perspectives in Cancer webinars.
February 19th 2021
Natalie S. Callander, MD, discusses the potential future of belantamab mafodotin-blmf in multiple myeloma.
January 28th 2021
Natalie S. Callander, MD, discusses the expanding role of belantamab mafodotin-blmf in multiple myeloma.
January 22nd 2021
Natalie S. Callander, MD, discusses selecting a frontline treatment strategy for patients with multiple myeloma.
October 11th 2017
Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses combinations in multiple myeloma.
October 10th 2017
Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses treatment considerations in relapsed and refractory multiple myeloma.